Agenus Inc.
2.36 %
-81.75 %
Yet to be announced
Company Overview
Agenus Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of immunological agents for the treatment of cancer. The company develops antibody therapeutics, adjuvants, and vaccines designed to treat cancerous tumors and infectious diseases.
Revenue Sources
PassBased on the company's financial statements and SEC filings, Agenus generates its revenue primarily from research and development collaborations, licensing agreements, and product sales related to its immunotherapy platforms. The company's core business activities are focused on developing cancer treatments and vaccines, which are halal activities.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $26.84m | $52.73m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $25.11m | $56.62m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $23.51m | $53.7m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $28.0m | $60.89m | - | - | 0.00% | 0.00% |
Looking at the financial data for the last four quarters, Agenus reports zero interest income and zero interest expense. The company appears to be operating without significant interest-bearing activities. While the company is generating revenue, it's still in development phase for many of its products, with ongoing clinical trials.
Operational Ethics
PassBased on review of the company's operations, SEC filings, and public information, there is no evidence of significant ongoing associations with entities involved in human rights violations. The company's primary operations and research facilities are located in the United States and the United Kingdom.
Comments